Jaguar Health, Inc. (JAGX)
About Jaguar Health, Inc.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $11.5M
- Net income
- -$53.6M
- Total assets
- $38.3M
- Market cap
- $2.0M
- Gross margin
- 67.2%
- Operating margin
- -398.8%
- Net margin
- -469.1%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $11.5M
- Cost of revenue
- $3.8M
- Gross profit
- $7.7M
- Operating expenses
- $53.6M
- Operating income
- -$45.9M
- Income tax
- $0
- Net income
- -$54.0M
- EPS (basic)
- $-22.97
- EPS (diluted)
- $-22.97
Balance sheet
- Total assets
- $38.3M
- Current assets
- $20.3M
- Total liabilities
- $57.0M
- Current liabilities
- $40.7M
- Shareholders’ equity
- -$18.7M
Cash flow
- Operating cash flow
- -$23.7M
- Investing cash flow
- -$41.0K
- Financing cash flow
- $23.7M
- Net cash flow
- -$57.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $2.0M
- EPS (diluted)
- $-22.97
- Shares outstanding
- 2.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 13, 2015
Jaguar Health, Inc. (JAGX) Stock Price
- Reported a net loss of $53.6M in FY2025.
- Revenue grew 166% from FY2021 to FY2025.
- Gross margin of 67.2%, net margin -469.1%.
- Trading 99% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Jaguar Health, Inc..
Write a review
News about Jaguar Health, Inc.
News & sentiment via Polygon.io
Jaguar Health, Inc.: frequently asked questions
Is Jaguar Health, Inc. an American company?
Jaguar Health, Inc. is a US-based company headquartered in San Francisco, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Jaguar Health, Inc. headquartered?
Jaguar Health, Inc. is headquartered in San Francisco, California, United States.
Is Jaguar Health, Inc. publicly traded?
Yes — Jaguar Health, Inc. is a publicly traded company. Its stock trades under the ticker symbol JAGX on the NASDAQ.
What does Jaguar Health, Inc. do?
Jaguar Health, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
